Cancer Treatment Reviews' 2026 Journal Metrics Score is 9.2, ranking Q1 in Oncology and 2 other subfields. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 10.80.
Middle 50%: 45–91 days
100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025
Cancer Treatment Reviews accepts papers a median of 63 days after submission, including peer review and revisions. That is faster than 91% of comparable journals with PubMed timing data.
Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
239 of 470 works · same type, year & subfield
27 works · same type, year & subfield
Above field-year expectation
of 2,437 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 2.69, so its typical recent paper runs about 169% above its field benchmark.
50.9% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2016–2025
470 OpenAlex works · 2021–2024
OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.
Select a MeSH signal to see how much Cancer Treatment Reviews publishes on it, from PubMed counts for the last five complete years.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Oncology | Q1 |
| Pulmonary and Respiratory Medicine | Q1 |
| Cancer Research | Q1 |
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
Cancer Treatment Reviews' 2026 Journal Metrics Score is 9.2, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
Cancer Treatment Reviews' best quartile is Q1. By OpenAlex subfield: Q1 in Oncology; Q1 in Pulmonary and Respiratory Medicine; Q1 in Cancer Research. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Cancer Treatment Reviews will not match this score exactly. Compare journals using one source at a time.
Cancer Treatment Reviews accepts papers a median of 63 days after submission across 100 recent PubMed records with both dates; the middle half took 45–91 days. This includes peer review, editorial handling, and revisions.
PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Cancer Treatment Reviews, which includes peer review and revisions, has a median of 63 days. For the time to a first decision, check the journal's own website.
Cancer Treatment Reviews' median of 63 days from submission to acceptance is faster than 91% of comparable journals with PubMed timing data.
OpenAlex lists an indicative article processing charge of $4,910 USD for Cancer Treatment Reviews. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.
Comparable journals include Critical Reviews in Oncology Hematology, Therapeutic Advances in Medical Oncology, Esmo Open, and Oncology in Clinical Practice. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.